Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer

医学 直肠检查 前列腺癌 生物统计学 医疗保健 普通外科 癌症 流行病学 内科学 法学 政治学
作者
Peter N. Schlegel,Clara Oromendia,Jonathan E. Shoag,Sameer Mittal,Michael F. Cosiano,Karla V. Ballman,Andrew J. Vickers,Jim C. Hu
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:199 (4): 947-953 被引量:66
标识
DOI:10.1016/j.juro.2017.10.021
摘要

No AccessJournal of UrologyAdult Urology1 Apr 2018Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer Joshua A. Halpern, Clara Oromendia, Jonathan E. Shoag, Sameer Mittal, Michael F. Cosiano, Karla V. Ballman, Andrew J. Vickers, and Jim C. Hu Joshua A. HalpernJoshua A. Halpern Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author , Clara OromendiaClara Oromendia Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York More articles by this author , Jonathan E. ShoagJonathan E. Shoag Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author , Sameer MittalSameer Mittal Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author , Michael F. CosianoMichael F. Cosiano Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author , Karla V. BallmanKarla V. Ballman Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York More articles by this author , Andrew J. VickersAndrew J. Vickers Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author , and Jim C. HuJim C. Hu Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York Financial interest and/or other relationship with Intuitive Surgical and Genomic Health. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.10.021AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Guidelines from the NCCN® (National Comprehensive Cancer Network®) advocate digital rectal examination screening only in men with elevated prostate specific antigen. We investigated the effect of prostate specific antigen on the association of digital rectal examination and clinically significant prostate cancer in a large American cohort. Materials and Methods: We evaluated the records of the 35,350 men who underwent digital rectal examination in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial for the development of clinically significant prostate cancer (Gleason 7 or greater). Followup was 343,273 person-years. The primary outcome was the rate of clinically significant prostate cancer among men with vs without suspicious digital rectal examination. We performed competing risks regression to evaluate the interaction between time varying suspicious digital rectal examination and prostate specific antigen. Results: A total of 1,713 clinically significant prostate cancers were detected with a 10-year cumulative incidence of 5.9% (95% CI 5.6–6.2). Higher risk was seen for suspicious vs nonsuspicious digital rectal examination. Increases in absolute risk were small and clinically irrelevant for normal (less than 2 ng/ml) prostate specific antigen (1.5% vs 0.7% risk of clinically significant prostate cancer at 10 years), clinically relevant for elevated (3 ng/ml or greater) prostate specific antigen (23.0% vs 13.7%) and modestly clinically relevant for equivocal (2 to 3 ng/ml) prostate specific antigen (6.5% vs 3.5%). Conclusions: Digital rectal examination demonstrated prognostic usefulness when prostate specific antigen was greater than 3 ng/ml, limited usefulness for less than 2 ng/ml and marginal usefulness for 2 to 3 ng/ml. These findings support the restriction of digital rectal examination to men with higher prostate specific antigen as a reflex test to improve specificity. It should not be used as a primary screening modality to improve sensitivity. References 1 : Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: data from the Pennsylvania Cancer Registry. Urol Oncol2016; 34: 335.e21. Google Scholar 2 : Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis2016; 19: 395. Google Scholar 3 : Early detection of prostate cancer by routine screening. JAMA1984; 252: 3261. Google Scholar 4 : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol1994; 151: 1283. Link, Google Scholar 5 : Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer1999; 84: 437. Google Scholar 6 : Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA1993; 269: 61. Google Scholar 7 : Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol2012; 61: 577. Google Scholar 8 : The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol2008; 54: 581. Google Scholar 9 : Early detection of prostate cancer: AUA Guideline. J Urol2013; 190: 419. Link, Google Scholar 10 : NCCN Guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw2016; 14: 509. Google Scholar 11 : Prognostic significance of digital rectal examination and prostate specific antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. J Urol2017; 197: 363. Link, Google Scholar 12 : Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials2000; 21: 273S. Google Scholar 13 : Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Urol2005; 173: 746. Link, Google Scholar 14 : A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc1999; 94: 496. Google Scholar 15 : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009; 360: 1310. Google Scholar 16 : Reevaluating PSA testing rates in the PLCO trial. N Engl J Med2016; 374: 1795. Google Scholar 17 : An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int2007; 99: 559. Google Scholar 18 : Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst2006; 98: 529. Google Scholar 19 : Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin2017; 33: 315. Google Scholar 20 : External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology2006; 68: 1152. Google Scholar 21 : Hand-assisted laparoscopic versus robot-assisted laparoscopic partial nephrectomy: comparison of short-term outcomes and cost. J Endourol Soc2013; 27: 182. Google Scholar 22 : Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Ovarian Cancer Screening Trial Project Team. Control Clin Trials2000; 21: 390S. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byTosoian J, Trock B, Morgan T, Salami S, Tomlins S, Spratt D, Siddiqui J, Kunju L, Botbyl R, Chopra Z, Pandian B, Eyrich N, Longton G, Zheng Y, Palapattu G, Wei J, Niknafs Y and Chinnaiyan A (2020) Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing ApproachJournal of Urology, VOL. 205, NO. 3, (732-739), Online publication date: 1-Mar-2021.Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland S and Polascik T (2018) Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass IndexJournal of Urology, VOL. 200, NO. 4, (758-766), Online publication date: 1-Oct-2018.Smith J (2018) This Month in Adult UrologyJournal of Urology, VOL. 199, NO. 4, (863-864), Online publication date: 1-Apr-2018. Volume 199Issue 4April 2018Page: 947-953Supplementary Materials Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.Keywordsearly detection of cancerprostate-specific antigendigital rectal examinationprostatic neoplasmsmass screeningAcknowledgmentsNCI (National Cancer Institute) provided access to NCI data collected in the PLCO Cancer Screening Trial.MetricsAuthor Information Joshua A. Halpern Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author Clara Oromendia Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York More articles by this author Jonathan E. Shoag Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author Sameer Mittal Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author Michael F. Cosiano Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York More articles by this author Karla V. Ballman Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York More articles by this author Andrew J. Vickers Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author Jim C. Hu Department of Urology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York Financial interest and/or other relationship with Intuitive Surgical and Genomic Health. More articles by this author Expand All Advertisement PDF downloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
4秒前
李爱国应助大橙子采纳,获得10
5秒前
magictoo发布了新的文献求助30
11秒前
13秒前
yang完成签到,获得积分10
13秒前
Minicoper发布了新的文献求助10
14秒前
快乐丸子完成签到,获得积分10
15秒前
简单而复杂完成签到,获得积分10
15秒前
大橙子发布了新的文献求助10
19秒前
张牧之完成签到 ,获得积分10
21秒前
冷冷暴力完成签到,获得积分10
23秒前
YYY完成签到,获得积分10
23秒前
23秒前
gujian完成签到 ,获得积分10
26秒前
帅气的秘密完成签到 ,获得积分10
27秒前
自然函发布了新的文献求助10
31秒前
冰冰双双完成签到,获得积分10
31秒前
开心夏旋完成签到 ,获得积分0
33秒前
我要读博士完成签到 ,获得积分10
36秒前
活泼的大船完成签到,获得积分10
36秒前
AFF完成签到,获得积分10
37秒前
38秒前
无私小小完成签到,获得积分10
39秒前
随心所欲完成签到 ,获得积分10
40秒前
润润轩轩完成签到 ,获得积分10
41秒前
CodeCraft应助大橙子采纳,获得10
41秒前
ZR完成签到,获得积分10
42秒前
magictoo完成签到,获得积分10
42秒前
陈昊发布了新的文献求助10
43秒前
zhangliangfu完成签到 ,获得积分10
43秒前
金石为开完成签到,获得积分10
43秒前
王QQ完成签到 ,获得积分10
45秒前
唐唐完成签到 ,获得积分10
49秒前
最棒哒完成签到 ,获得积分10
49秒前
鸣鸣完成签到,获得积分10
50秒前
123321完成签到 ,获得积分10
51秒前
卓若之完成签到 ,获得积分10
52秒前
苯二氮卓完成签到,获得积分10
53秒前
温暖完成签到 ,获得积分10
55秒前
mojomars完成签到,获得积分10
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022